ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

Clinical trial NCT06716021 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06716021
Sponsor: Milestone Pharmaceuticals Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Atrial Fibrillation

Start date: 2027-01-01
Primary completion: 2029-01-01
Enrollment: 750

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.